GlassScriptPhysician profile
Kyle David Mills
NPI 1841795507
$3,813.18
in general payments reported to CMS, 2019-2025
31 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $928 · 2023: $859 · 2024: $801 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.55 | 2021-2025 | |
| Amgen INC. | $481.84 | 2021-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $417.33 | 2022 | |
| Pfizer INC. | $357.01 | 2023-2025 | |
| Novo Nordisk INC | $209.07 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $205.46 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $171.03 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Viiv Healthcare Company | $113.36 | 2023-2025 | Apretude |
| Exact Sciences Corporation | $108.14 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $92.89 | 2021-2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $88.88 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $69.53 | 2023-2024 | Myrbetriq, Veozah |
| Halozyme INC | $45.18 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $44.05 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $40.69 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $39.75 | 2025 | Qutenza |
| Gilead Sciences, INC. | $39.61 | 2025 | |
| Antares Pharma, INC. | $37.51 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $27.40 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $26.65 | 2021-2024 | Unithroid |
| Almatica Pharma LLC | $26.39 | 2024 | Loreev Xr |
| Neuronetics, INC. | $22.17 | 2025 | Neurostar Tms Therapy System |
| Phathom Pharmaceuticals, INC. | $20.56 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $20.24 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.49 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $16.15 | 2022 | |
| Medtronic, INC. | $15.75 | 2025 | Minimed 780g |
| Radius Health, INC. | $15.74 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $14.60 | 2021 | |
| Sanofi Pasteur INC. | $14.18 | 2021 | |
| Redhill Biopharma INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.